Mohamed A. Shawarby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed A. Shawarby has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ayesha Ahmed
Department of Pathology College of Medicine, Imam Abdulrahman Bin Faisal University and King Fahd Hospital of the University Dammam Kingdom of Saudi Arabia
3 shared publications - Dalal M Al Tamimi
Department of Pathology, University of Dammam and King Fahd Hospital of the University, KSA
3 shared publications - Abdulaziz Al-Quorain
College of Medicine and Medical Sciences, King Faisal University, Dammam, Saudi Arabia
1 shared publication Ahmad S Kamel
College of Medicine University of Dammam Al-Khobar P.O. Box 2208 31952 Dammam Saudi Arabia
1 shared publicationAhmed A. Al-Sayyah
1 shared publication- Amal A Al-Odaini
Division of Medical Oncology, Department of Medicine, McGill University Health Center, Royal Victoria Hospital, Montreal, QC, Canada
1 shared publication
Latest Publications
- Open Access
- 1 April 2016
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 11 (2) , 134-139
Prerequisites for histopathological evaluation of reduction mammoplasty specimens: Recommendations based on an audit in a tertiary care hospital
- 1 April 2016
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 11 (2) , 134-139
Open AccessPrerequisites for histopathological evaluation of reduction mammoplasty specimens: Recommendations based on an audit in a tertiary care hospital
- Open Access
- 26 February 2015
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 15 (1) , 2
Primary gastric actinomycosis: report of a case diagnosed in a gastroscopic biopsy
Primary gastric actinomycosis is extremely rare, the appendix and ileocecal region being the most commonly involved sites in abdominopelvic actinomycosis. Herein, we report a case of primary gastric actinomycosis. The diagnosis was made on microscopic evaluation of gastroscopic biopsy specimens. To the best of our knowledge, this is the third case to be reported in the literature, in which the diagnosis was made in a gastroscopic biopsy rather than a resection specimen. An 87-year-old Saudi male on medication for cardiomyopathy, premature ventricular contractions, renal impairment, hypertension, and dyslipidemia, presented to the emergency department with acute diffuse abdominal pain, abdominal distension, constipation and vomiting for two days, with no history of fever, abdominal surgery or trauma. The patient was admitted to the hospital with an impression of gastric outlet obstruction. Based on radiologic and gastroscopic findings, a non-infectious etiology was suspected, possibly adenocarcinoma or lymphoma. Gastroscopic biopsies showed an actively inflamed, focally ulcerated atrophic fundic mucosa along with fragments of a fibrinopurulent exudate containing brownish, iron negative pigment and abundant filamentous bacteria, morphologically consistent with Actinomyces. Althuogh extremely rare, primary gastric actinomycosis should be considered in the differential diagnosis of radiologic and gastroscopic diffuse gastric wall thickening and submucosal tumor-like or infiltrative lesions, particularly in patients with history of abdominal surgery or trauma, or those receiving extensive medication. A high level of suspicion is required by the pathologist to achieve diagnosis in gastroscopic biopsies. Subtle changes such as the presence of a pigmented inflammatory exudate should alert the pathologist to perform appropriate special stains to reveal the causative organism.
- 26 February 2015
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 15 (1) , 2
Open AccessPrimary gastric actinomycosis: report of a case diagnosed in a gastroscopic biopsy
Primary gastric actinomycosis is extremely rare, the appendix and ileocecal region being the most commonly involved sites in abdominopelvic actinomycosis. Herein, we report a case of primary gastric actinomycosis. The diagnosis was made on microscopic evaluation of gastroscopic biopsy specimens. To the best of our knowledge, this is the third case to be reported in the literature, in which the diagnosis was made in a gastroscopic biopsy rather than a resection specimen. An 87-year-old Saudi male on medication for cardiomyopathy, premature ventricular contractions, renal impairment, hypertension, and dyslipidemia, presented to the emergency department with acute diffuse abdominal pain, abdominal distension, constipation and vomiting for two days, with no history of fever, abdominal surgery or trauma. The patient was admitted to the hospital with an impression of gastric outlet obstruction. Based on radiologic and gastroscopic findings, a non-infectious etiology was suspected, possibly adenocarcinoma or lymphoma. Gastroscopic biopsies showed an actively inflamed, focally ulcerated atrophic fundic mucosa along with fragments of a fibrinopurulent exudate containing brownish, iron negative pigment and abundant filamentous bacteria, morphologically consistent with Actinomyces. Althuogh extremely rare, primary gastric actinomycosis should be considered in the differential diagnosis of radiologic and gastroscopic diffuse gastric wall thickening and submucosal tumor-like or infiltrative lesions, particularly in patients with history of abdominal surgery or trauma, or those receiving extensive medication. A high level of suspicion is required by the pathologist to achieve diagnosis in gastroscopic biopsies. Subtle changes such as the presence of a pigmented inflammatory exudate should alert the pathologist to perform appropriate special stains to reveal the causative organism.
- Open Access
- 20 November 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (11) , e113350
Novel KRAS Gene Mutations in Sporadic Colorectal Cancer
In this article, we report 7 novel KRAS gene mutations discovered while retrospectively studying the prevalence and pattern of KRAS mutations in cancerous tissue obtained from 56 Saudi sporadic colorectal cancer patients from the Eastern Province. Genomic DNA was extracted from formalin-fixed, paraffin-embedded cancerous and noncancerous colorectal tissues. Successful and specific PCR products were then bi-directionally sequenced to detect exon 4 mutations while Mutector II Detection Kits were used for identifying mutations in codons 12, 13 and 61. The functional impact of the novel mutations was assessed using bioinformatics tools and molecular modeling. KRAS gene mutations were detected in the cancer tissue of 24 cases (42.85%). Of these, 11 had exon 4 mutations (19.64%). They harbored 8 different mutations all of which except two altered the KRAS protein amino acid sequence and all except one were novel as revealed by COSMIC database. The detected novel mutations were found to be somatic. One mutation is predicted to be benign. The remaining mutations are predicted to cause substantial changes in the protein structure. Of these, the Q150X nonsense mutation is the second truncating mutation to be reported in colorectal cancer in the literature. Our discovery of novel exon 4 KRAS mutations that are, so far, unique to Saudi colorectal cancer patients may be attributed to environmental factors and/or racial/ethnic variations due to genetic differences. Alternatively, it may be related to paucity of clinical studies on mutations other than those in codons 12, 13, 61 and 146. Further KRAS testing on a large number of patients of various ethnicities, particularly beyond the most common hotspot alleles in exons 2 and 3 is needed to assess the prevalence and explore the exact prognostic and predictive significance of the discovered novel mutations as well as their possible role in colorectal carcinogenesis.
- 20 November 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (11) , e113350
Open AccessNovel KRAS Gene Mutations in Sporadic Colorectal Cancer
In this article, we report 7 novel KRAS gene mutations discovered while retrospectively studying the prevalence and pattern of KRAS mutations in cancerous tissue obtained from 56 Saudi sporadic colorectal cancer patients from the Eastern Province. Genomic DNA was extracted from formalin-fixed, paraffin-embedded cancerous and noncancerous colorectal tissues. Successful and specific PCR products were then bi-directionally sequenced to detect exon 4 mutations while Mutector II Detection Kits were used for identifying mutations in codons 12, 13 and 61. The functional impact of the novel mutations was assessed using bioinformatics tools and molecular modeling. KRAS gene mutations were detected in the cancer tissue of 24 cases (42.85%). Of these, 11 had exon 4 mutations (19.64%). They harbored 8 different mutations all of which except two altered the KRAS protein amino acid sequence and all except one were novel as revealed by COSMIC database. The detected novel mutations were found to be somatic. One mutation is predicted to be benign. The remaining mutations are predicted to cause substantial changes in the protein structure. Of these, the Q150X nonsense mutation is the second truncating mutation to be reported in colorectal cancer in the literature. Our discovery of novel exon 4 KRAS mutations that are, so far, unique to Saudi colorectal cancer patients may be attributed to environmental factors and/or racial/ethnic variations due to genetic differences. Alternatively, it may be related to paucity of clinical studies on mutations other than those in codons 12, 13, 61 and 146. Further KRAS testing on a large number of patients of various ethnicities, particularly beyond the most common hotspot alleles in exons 2 and 3 is needed to assess the prevalence and explore the exact prognostic and predictive significance of the discovered novel mutations as well as their possible role in colorectal carcinogenesis.
- Open Access
- 29 August 2014
- Published by Sciedu Press in Case Reports in Clinical Pathology
- Vol. 2 (1)
Synchronous primary colonic and early gallbladder carcinomas: report of a rare case
- 29 August 2014
- Published by Sciedu Press in Case Reports in Clinical Pathology
- Vol. 2 (1)
Open AccessSynchronous primary colonic and early gallbladder carcinomas: report of a rare case
- Open Access
- 1 January 2013
- Published by Edorium Journals Pvt. Ltd. in International Journal of Case Reports and Images
- Vol. 4 (10) , 527-531
Chondroid lipoma, a rare lipomatous tumor: A case series
Chondroid lipoma is a rare, benign lipomatous tumor that may be mistaken histologically for a liposarcoma or chondrosarcoma. Herein, two cases of chondroid lipoma are reported in two Egyptian females aged 38 and 51 years and literature about this rare tumor briefly reviewed with discussion of diagnostic criteria that may help distinguish it from other tumors with overlapping histologic features. The tumor was subcutaneous in both cases. One was located in the right knee area, the other in an infra-mammary location on the right side of the chest. Grossly, both neoplasms were encapsulated and exhibited a nodular, myxoid cut surface. Histologically, they consisted of an abundant myxoid and chondroid stroma interspersed by small round cells with eosinophilic or vacuolated cytoplasm, signet ring lipoblast-like cells, adipocytes and foci of mature adipose tissue. Immunohistochemically, diffuse reactivity of the neoplastic cells for vimentin and variable reactivity for S-100 protein were present in both cases. One case also showed focal immunoreactivity for CD68. The Ki67 proliferative index was less than 5%. The common differentials like myxoid liposarcoma and extraskeletal myxoid chondrosarcoma were ruled out based mainly on pure histologic criteria. Both patients underwent simple curative excision and were tumor free for at least one and three years after surgery, respectively. Because chondroid lipoma is easily misdiagnosed as a sarcoma of either adipose tissue or cartilage, a high level of suspicion by the pathologist and familiarity with its features are of practical importance to avoid misdiagnosis and overtreatment.
- 1 January 2013
- Published by Edorium Journals Pvt. Ltd. in International Journal of Case Reports and Images
- Vol. 4 (10) , 527-531
Open AccessChondroid lipoma, a rare lipomatous tumor: A case series
Chondroid lipoma is a rare, benign lipomatous tumor that may be mistaken histologically for a liposarcoma or chondrosarcoma. Herein, two cases of chondroid lipoma are reported in two Egyptian females aged 38 and 51 years and literature about this rare tumor briefly reviewed with discussion of diagnostic criteria that may help distinguish it from other tumors with overlapping histologic features. The tumor was subcutaneous in both cases. One was located in the right knee area, the other in an infra-mammary location on the right side of the chest. Grossly, both neoplasms were encapsulated and exhibited a nodular, myxoid cut surface. Histologically, they consisted of an abundant myxoid and chondroid stroma interspersed by small round cells with eosinophilic or vacuolated cytoplasm, signet ring lipoblast-like cells, adipocytes and foci of mature adipose tissue. Immunohistochemically, diffuse reactivity of the neoplastic cells for vimentin and variable reactivity for S-100 protein were present in both cases. One case also showed focal immunoreactivity for CD68. The Ki67 proliferative index was less than 5%. The common differentials like myxoid liposarcoma and extraskeletal myxoid chondrosarcoma were ruled out based mainly on pure histologic criteria. Both patients underwent simple curative excision and were tumor free for at least one and three years after surgery, respectively. Because chondroid lipoma is easily misdiagnosed as a sarcoma of either adipose tissue or cartilage, a high level of suspicion by the pathologist and familiarity with its features are of practical importance to avoid misdiagnosis and overtreatment.
- Open Access
- 24 June 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 57
Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients
Breast cancers which demonstrate EGFR protein expression, gene amplification and/or gene mutations may benefit therapeutically from tyrosine kinase inhibitors. In Western studies, EGFR protein expression has been demonstrated in 7-36% of breast cancer patients, while gene amplification has been found in around 6% of cases and mutations were either absent or extremely rare. Studies addressing EGFR protein expression and gene amplification in Saudi breast cancer patients are extremely scanty and the results reported have been mostly non-conclusive. Herein we report the prevalence of EGFR protein expression and gene amplification in a cohort of Saudi breast cancer patients.
- 24 June 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 57
Open AccessVery low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients
Breast cancers which demonstrate EGFR protein expression, gene amplification and/or gene mutations may benefit therapeutically from tyrosine kinase inhibitors. In Western studies, EGFR protein expression has been demonstrated in 7-36% of breast cancer patients, while gene amplification has been found in around 6% of cases and mutations were either absent or extremely rare. Studies addressing EGFR protein expression and gene amplification in Saudi breast cancer patients are extremely scanty and the results reported have been mostly non-conclusive. Herein we report the prevalence of EGFR protein expression and gene amplification in a cohort of Saudi breast cancer patients.
- Open Access
- 21 May 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 223
Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study
Breast cancer is not a single entity but a diverse group of entities. Advances in gene expression profiling and immunohistochemistry as its surrogate marker have led to the unmasking of new breast cancer molecular subtypes, resulting in the emergence of more elaborate classification systems that are therapeutically and prognostically more predictive. Molecular class distribution across various ethnic groups may also reveal variations that can lead to different clinical outcomes in different populations.
- 21 May 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 223
Open AccessProtein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study
Breast cancer is not a single entity but a diverse group of entities. Advances in gene expression profiling and immunohistochemistry as its surrogate marker have led to the unmasking of new breast cancer molecular subtypes, resulting in the emergence of more elaborate classification systems that are therapeutically and prognostically more predictive. Molecular class distribution across various ethnic groups may also reveal variations that can lead to different clinical outcomes in different populations.